摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-6-(4,5-diphenylimidazol-1-yl)purine | 891497-96-4

中文名称
——
中文别名
——
英文名称
2-chloro-6-(4,5-diphenylimidazol-1-yl)purine
英文别名
2-chloro-6-(4,5-diphenylimidazol-1-yl)-7H-purine
2-chloro-6-(4,5-diphenylimidazol-1-yl)purine化学式
CAS
891497-96-4
化学式
C20H13ClN6
mdl
——
分子量
372.816
InChiKey
SBMIGSUMNXXGJA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.5
  • 重原子数:
    27
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    72.3
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-chloro-6-(4,5-diphenylimidazol-1-yl)purine1-Α-氯-3,5-二-O-对甲苯甲酰基-2-脱氧-D-呋喃核糖 在 sodium hydride 作用下, 以 二氯甲烷乙腈 为溶剂, 反应 22.0h, 以100%的产率得到2-chloro-9-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-6-(4,5-diphenylimidazol-1-yl)purine
    参考文献:
    名称:
    6-(取代的咪唑-1-基)嘌呤与2-脱氧-3,5-二-O-(对甲苯甲酰基)-α-d- e-硝基-戊呋喃糖基氯的区域特异性和高立体选择性偶联。二元溶剂混合物中的钠盐糖基化:克拉屈滨1的改进合成
    摘要:
    的6-(取代咪唑-1-基)嘌呤钠盐的糖基化与2-脱氧-3,5-二- Ö - (p甲苯甲酰)-α- d -赤-戊呋喃糖酰氯继续进行N9异构体的区域特异性形成。在C6连接的咪唑部分上具有亲脂性取代基的基础底物更易溶于有机溶剂,并且通过二元溶剂混合物可进一步提高溶解度。选择性溶剂化也减少了氯糖的异构化程度。在极性溶剂中生成的改性嘌呤钠盐的搅拌反应混合物与受保护的2-脱氧糖氯化物在非极性溶剂中的冷却溶液的搅拌反应产生具有N9区域化学作用和增强的β/α构型比的2'-脱氧核苷衍生物。在冷乙腈中使用2-氯-6-(取代的咪唑-1-基)嘌呤盐和在冷二氯甲烷中使用氯糖的二元溶剂方法的应用,可得出定量定量的β-异头2'-脱氧核苷N9异构体的收率中间体。直接氨解(NH此类中间体的3 / MeOH)或咪唑环的苄基化反应,然后咪唑鎓盐的轻度氨解产生了临床抗癌药物克拉屈滨(2-chloro-2'-deoxyadenosine)的高收率。
    DOI:
    10.1021/jo061282+
  • 作为产物:
    参考文献:
    名称:
    Structure and Synthesis of 6-(Substituted-imidazol-1-yl)purines:  Versatile Substrates for Regiospecific Alkylation and Glycosylation at N91
    摘要:
    X-ray crystal structures of several 6-(azolyl) purine base and nucleoside derivatives show essentially coplanar conformations of the purine and appended 6-(azolyl) rings. However, the planes of the purine and imidazole rings are twisted similar to 57 degrees in a 2-chloro-6-(4,5-diphenylimidazol-1-yl) purine nucleoside, and a twist angle of similar to 61 degrees was measured between the planes of the purine and pyrrole rings in the structure of a 6-(2,5-dimethylpyrrol-1-yl) purine nucleoside derivative. Shielding "above" N7 of the purine ring by a proximal C-H on the 6-azolyl moiety is apparent with the coplanar compounds, but this effect is diminished in those without coplanarity. Syntheses of 6-(azolyl)purines from both base and nucleoside starting materials are described. Treatment of 2,6- dichloropurine with imidazole gave 2-chloro-6-(imidazol)-yl)purine. Modified Appel reactions at C6 of trityl-protected hypoxanthine and guanine derivatives followed by detritylation gave 6-(imidazol-1-yl)- and 2-amino-6-(imidazol-1-yl) purines. Imidazole was introduced at C6 of 2',3',5'-tri-O-acetylinosine by a modified Appel reaction, and solvolysis of the glycosyl linkage gave 6-(imidazol-1-yl) purine. Guanosine triacetate was transformed into the protected 2,6-dichloropurine nucleoside, which was subjected to SNAr displacement with imidazoles at C6 followed by glycosyl solvolysis to provide 2-chloro-6-(substituted-imidazol-1-yl) purines. Potential applications of these purine derivatives are outlined.
    DOI:
    10.1021/jo060340o
点击查看最新优质反应信息

文献信息

  • Regiospecific N9 Alkylation of 6-(Heteroaryl)purines:  Shielding of N7 by a Proximal Heteroaryl C−H<sup>1</sup>
    作者:Minghong Zhong、Morris J. Robins
    DOI:10.1021/jo061759h
    日期:2006.11.1
    agents. Treatment of 6-(2-butylimidazol-1-yl)-2-chloropurine (9) with sodium hydride in DMF followed by addition of ethyl iodide resulted in exclusive formation of 6-(2-butylimidazol-1-yl)-2-chloro-9-ethylpurine (10), whereas identical treatment of 2-chloro-6-(4,5-diphenylimidazol-1-yl)purine (11) produced a regioisomeric mixture 12/13 (N9/N7, ∼5:1). The linked imidazole and purine rings are coplanar
    嘌呤烷基化一直困扰着N9(通常需要),N7和其他区域异构体的混合物的形成。我们已经开发了合成6-(偶氮基)嘌呤衍生物的方法,这些衍生物的X射线晶体结构显示了所连接的吡咯-嘌呤环的基本共面构象。这样的环取向将吡咯的CHH定位在嘌呤的N7上方,这导致对N7的保护免受烷基化剂的影响。在DMF中用氢化钠处理6-(2-丁基咪唑-1-基)-2-氯嘌呤(9),然后加入碘乙烷,导致仅形成6-(2-丁基咪唑-1-基)-2-氯-9-乙基嘌呤(10),而2-氯-6-(4,5-二苯基咪唑-1-基)嘌呤的相同处理(11)则产生区域异构混合物12/ 13(N9 / N7,〜5:1)。链接的咪唑和嘌呤环在共面9(丁基侧链从嘌呤环延伸远离和C-H是在N7),但被旋转~57°在11,并且在更笨重唑取代11没有防止形成N7的较小的区域异构体13。现在可以容易地获得各种区域异构纯的9-烷基嘌呤。
  • Methods For Selective N-9 Glycosylation of Purines
    申请人:Robins Morris J.
    公开号:US20080207891A1
    公开(公告)日:2008-08-28
    A process for providing regiospecific and highly stereoselective synthesis of 9-β anomeric purine nucleoside analogs is described. The introduction of the sugar moiety on to 6-(azolyl)-substituted purine bases is performed so that highly stereoselective formation of the β anomers of only the 9 position regioisomers of the purine nucleoside analogs (either D or L enantiomers) is obtained. This regiospecific and stereoselective introduction of the sugar moiety allows the synthesis of nucleoside analogs, and in particular 2′-deoxy, 3′-deoxy, 2′-deoxy-2′-halo-arabino and 2′,3′-dideoxy-2′-halo-threo purine nucleoside analogs, in high yields without formation of the 7-positional regioisomers. Processes for providing novel 6-(azolyl)purines for the regiospecific and highly stereoselective synthesis of 9-β anomeric purine nucleoside analogs are described. The compounds are drugs or intermediates to drugs.
    本文描述了一种提供9-β异构嘌呤核苷类似物的区域特异性和高度立体选择性合成的方法。将糖基引入到6-(咪唑基)-取代的嘌呤碱基上,以获得嘌呤核苷类似物的β异构体的高度立体选择性形成(D或L对映体)。这种区域特异性和立体选择性引入糖基的方法,允许高产率地合成核苷类似物,特别是2'-去氧、3'-去氧、2'-去氧-2'-卤代阿拉伯糖和2',3'-二去氧-2'-卤代-threo嘌呤核苷类似物,而不形成7位异构体。本文还描述了提供新型6-(咪唑基)嘌呤用于区域特异性和高度立体选择性合成9-β异构嘌呤核苷类似物的方法。这些化合物是药物或药物中间体。
  • Methods for selective N-9 glycosylation of purines
    申请人:Brigham Young University
    公开号:US07855285B2
    公开(公告)日:2010-12-21
    A process for providing regiospecific and highly stereoselective synthesis of 9-β anomeric purine nucleoside analogs is described. The introduction of the sugar moiety on to 6-(azolyl)-substituted purine bases is performed so that highly stereoselective formation of the β anomers of only the 9 position regioisomers of the purine nucleoside analogs (either D or L enantiomers) is obtained. This regiospecific and stereoselective introduction of the sugar moiety allows the synthesis of nucleoside analogs, and in particular 2′-deoxy, 3′-deoxy, 2′-deoxy-2′-halo-arabino and 2′,3′-dideoxy-2′-halo-threo purine nucleoside analogs, in high yields without formation of the 7-positional regioisomers. Processes for providing novel 6-(azolyl)purines for the regiospecific and highly stereoselective synthesis of 9-β anomeric purine nucleoside analogs are described. The compounds are drugs or intermediates to drugs.
    本文描述了一种提供9-β异构嘌呤核苷类似物的区域特异性和高度立体选择性合成的过程。将糖基引入到6-(唑基)-取代的嘌呤碱基上,以获得仅嘌呤核苷类似物的9位区异构体(D或L对映体)的β异构体的高度立体选择性形成。这种区域特异性和立体选择性的糖基引入允许合成核苷类似物,特别是高产率地合成2'-去氧、3'-去氧、2'-去氧-2'-卤代阿拉伯糖和2',3'-二去氧-2'-卤代-葡萄糖嘌呤核苷类似物,而不形成7位区异构体。本文还描述了提供新型6-(唑基)嘌呤用于区域特异性和高度立体选择性合成9-β异构嘌呤核苷类似物的过程。这些化合物是药物或药物中间体。
  • WO2006/138396
    申请人:——
    公开号:——
    公开(公告)日:——
  • US7855285B2
    申请人:——
    公开号:US7855285B2
    公开(公告)日:2010-12-21
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺